1459-48-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(1-ADAMANTYL)ANILINE is used as a reactant in the preparation of pyrroledione derivatives, which are inhibitors of glycogen synthase kinase-3 (GSK-3). These inhibitors play a crucial role in the development of novel therapeutic agents for the treatment of various diseases, including neurodegenerative disorders, diabetes, and cancer. The adamantyl group in 4-(1-ADAMANTYL)ANILINE provides structural rigidity and enhances the binding affinity of the resulting pyrroledione derivatives to GSK-3, thereby improving their inhibitory potency.

InChI:InChI=1/C16H21N/c17-15-3-1-14(2-4-15)16-8-11-5-12(9-16)7-13(6-11)10-16/h1-4,11-13H,5-10,17H2

Upstream product

• 1459-49-0 1-(4-nitrophenyl)adamantane 
• 768-90-1 1-Adamantyl bromide 
• 62-53-3 aniline 
• 768-95-6 1-adamanthanol 
• 7123-78-6 4-(adamant-1-yl)benzoic acid 
• 1247829-32-8 tert-butyl [4-(adamantan-1-yl)phenyl]carbamate 
• 540-37-4 p-aminoiodobenzene 
• 103-84-4 Acetanilid 
• 1459-50-3 N-(4-((3r,5r,7r)-adamantan-1-yl)phenyl)acetamide 
• 71-43-2 benzene 
• 108-88-3 toluene 
• 175881-22-8 4-(1-adamantyl)benzoic acid chloride 
• 7164-55-8 ethyl 4-(adamantan-1-yl)benzoate 
• 1459-55-8 4-(1-adamantyl)toluene 

Downstream Products

• 1459-50-3 N-(4-((3r,5r,7r)-adamantan-1-yl)phenyl)acetamide 
• 7163-95-3 4-(adamantan-1-yl)benzonitrile 
• 59974-40-2 1-(4-chlorophenyl)adamantane 
• 1247829-35-1 ethyl {[4-(adamantan-1-yl)phenyl]amino}oxoacetate 
• 1350474-50-8 N-[4-(1-adamantyl)phenyl]-2-[3-phenyl-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-ylthio]acetamide 
• 7164-55-8 ethyl 4-(adamantan-1-yl)benzoate 
• 7164-56-9 1-<4-Ethoxymethyl-phenyl>-adamantan 
• 7131-09-1 1-(4-(bromomethyl)phenyl)adamantane 
• 7131-08-0 (4-(adamantan-1-yl)phenyl)methanol 
• 7123-78-6 4-(adamant-1-yl)benzoic acid 
• 2245-43-4 4-(1-Adamantyl)bromobenzene 

Relevant academic research and scientific papers

Modes of Micromolar Host-Guest Binding of β-Cyclodextrin Complexes Revealed by NMR Spectroscopy in Salt Water

Multitopic supramolecular guests with finely tuned affinities toward widely explored cucurbit[n]urils (CBs) and cyclodextrins (CDs) have been recently designed and tested as functional components of advanced supramolecular systems. We employed various spa

Nitrogen-containing compound, electronic element, and electronic device

The invention relates to a nitrogen-containing compound, an electronic element comprising the nitrogen-containing compound, and an electronic device comprising the electronic element. According to thenitrogen-containing compound, an adamantyl group and a bis (triarylamine) structure are combined to form a core structure, the whole molecule forms a large conjugated system, meanwhile, the molecularrigidity is improved, and the thermal stability is remarkably improved. When the nitrogen-containing compound is applied to the electronic element, the luminous efficiency or the power generation efficiency of the electronic element can be improved, and the service life can be prolonged.

NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

Adamantylation of N-aryl and N-arylalkyl acetamides in trifluoroacetic acid

Alkylation of N-aryl and N-arylalkyl acetamides with hydroxy adamantane derivatives in trifluoroacetic acid was studied. The differentiating effect of trifluoroacetic acid on the regio-selectivity of adamantylation of o-alkyl-substituted acetanilides was established, leading to energetically more stable products of para-substitution with respect to the alkyl group (the content of para-alkyl isomers is 93–94percent). This enabled the synthesis of adamantylaminoarenes in 83–99percent yields and with 95–99percent purity.

4-(1-Adamantyl)phenylalkylamines with potential antiproliferative activity

Background: In our previous publications we have described the synthesis of aminosubstituded diaryl adamantanes and their pharmacological evaluation in vitro and in vivo against many cancer cell lines. More recently, we have reported the synthesis of mono

Plasminogen Activator Inhibitor-1 Inhibitor

The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

REACTION OF 1-HYDROXYADAMANTANE WITH AROMATIC AMINES IN THE PRESENCE OF ORTHO-ALKYLATION CATALYSTS

The reaction of 1-hydroxyadamantane with aniline and N-methylaniline in the presence of hydrochlorides of the corresponding amines and aluminum anilide gives a mixture of mono- and di(1-adamantyl)anilines and 4,4'-di(1-adamantyl)diphenylamine, in which th

Alkylation and aralkylation of aromatic amines

Compounds having the formula I STR1 as well as salts or metal salt complexes thereof, in which formula I n, R1, R2 and Z have the meanings given in claim 1, can be prepared under mild reaction conditions by reacting 1.0 mole of an ar

REACTIONS OF 1.3-DEHYDROADAMANTANE (3.3.1-PROPELLANE SYSTEM) WITH CH- AND NH-ACIDS.

Reactions of 1.3-dehydroadamantane with aniline in the presence of its hydrochloride, p-toluenesulfamide, and malonic ester are investigated.